- Conditions
- Breast Cancer
- Interventions
- filgrastim, carboplatin, cyclophosphamide, mesna, paclitaxel, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- St. Louis University
- Other
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1994
- U.S. locations
- 3
- States / cities
- Indianapolis, Indiana • St Louis, Missouri • Memphis, Tennessee
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 145–168
of 1,114
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Plasma Cell Leukemia in Remission, Plasma Cell Myeloma
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Filgrastim, Laboratory Biomarker Analysis, Lenalidomide, pheresis, Melphalan, Palifermin, Total Marrow Irradiation
- Procedure · Drug · Biological + 2 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Autologous Stem Cell Transplantation
- Interventions
- G-CSF plus plerixafor
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years to 78 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 8
- States / cities
- Duarte, California • Tampa, Florida • Atlanta, Georgia + 5 more
- Conditions
- Fanconi Anemia, Severe Aplastic Anemia, Myelodysplastic Syndromes, T Cell Receptor Alpha/Beta Depletion, Telomere Biology Disorder, Bone Marrow Failure, Dyskeratosis Congenita, Telomere Biology Disorders
- Interventions
- Total Body Irradiation (TBI) (Plan 1), Cyclophosphamide (CY) (Plan 1), Fludarabine (FLU), Methylprednisolone (MP), Donor mobilized PBSC infusion, G-CSF, Cyclophosphamide (CY) (Plan 2), Rituximab, Busulfan, Alemtuzumab, Melphalan
- Drug · Device
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 65 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2029
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Sarcoma
- Interventions
- filgrastim, doxorubicin hydrochloride, ifosfamide, mesna, vincristine sulfate, conventional surgery, brachytherapy, low-LET cobalt-60 gamma ray therapy, low-LET electron therapy, low-LET photon therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2006
- U.S. locations
- 7
- States / cities
- Wichita, Kansas • New Orleans, Louisiana • Memphis, Tennessee + 4 more
- Conditions
- Multiple Myeloma
- Interventions
- filgrastim, cisplatin, cyclophosphamide, dexamethasone, etoposide, thalidomide
- Biological · Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2007
- U.S. locations
- 93
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 60 more
- Conditions
- Lymphoma
- Interventions
- bleomycin sulfate, filgrastim, cyclophosphamide, cytarabine, doxorubicin hydrochloride, etoposide, leucovorin calcium, methotrexate, prednisone, trimethoprim-sulfamethoxazole, vincristine sulfate, radiation therapy, Intrathecal cytarabine
- Biological · Drug · Radiation
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1994 – 2011
- U.S. locations
- 85
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 53 more
- Conditions
- Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Decitabine, Decitabine and Cedazuridine, Filgrastim, Imaging Procedure, Lumbar Puncture
- Procedure · Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 21 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Aurora, Colorado • Atlanta, Georgia + 10 more
- Conditions
- Breast Cancer
- Interventions
- filgrastim, autologous bone marrow transplantation, peripheral blood stem cell transplantation, indium In 111 monoclonal antibody BrE-3, yttrium Y 90 monoclonal antibody BrE-3
- Biological · Procedure · Radiation
- Lead sponsor
- Cancer Research Institute of Contra Costa
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2004
- U.S. locations
- 2
- States / cities
- San Francisco, California • Aurora, Colorado
- Conditions
- Stage III Adult Soft Tissue Sarcoma, Recurrent Adult Soft Tissue Sarcoma, Stage IVA Adult Soft Tissue Sarcoma, Stage IIB Adult Soft Tissue Sarcoma, Stage IIC Adult Soft Tissue Sarcoma
- Interventions
- doxorubicin, filgrastim, ifosfamide, biological response modifier therapy, brachytherapy, chemotherapy, colony-stimulating factor therapy, conventional surgery, cytokine therapy, intraoperative radiotherapy, radiation therapy, surgery
- Drug · Procedure
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 216
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 165 more
- Conditions
- Neuroblastoma
- Interventions
- filgrastim, sargramostim, carboplatin, cisplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, etoposide phosphate, ifosfamide, isotretinoin, melphalan, thiotepa, vincristine sulfate, conventional surgery, peripheral blood stem cell transplantation, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 30 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2012
- U.S. locations
- 8
- States / cities
- Atlanta, Georgia • Boston, Massachusetts • Portland, Oregon + 4 more
- Conditions
- Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL), Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)
- Interventions
- Ibrutinib, HD- Methotrexate (MTX), Rituximab + HD- Methotrexate (MTX), procarbazine
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Multiple Myeloma
- Interventions
- Activated marrow infiltrating lymphocytes, Allogeneic Myeloma Vaccine, Cyclophosphamide, Filgrastim, Leukapheresis, Melphalan, Autologous stem cell transplant
- Biological · Drug · Procedure
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2020
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Leukemia, Myelodysplastic Syndromes
- Interventions
- anti-thymocyte globulin, fludarabine phosphate, thiotepa, peripheral blood stem cell transplantation, total-body irradiation
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 60 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 9
- States / cities
- Tampa, Florida • Atlanta, Georgia • Indianapolis, Indiana + 5 more
- Conditions
- Ewing Sarcoma of Bone, Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Interventions
- radiation therapy, therapeutic conventional surgery, etoposide, ifosfamide, doxorubicin hydrochloride, cyclophosphamide, vincristine sulfate, topotecan hydrochloride, filgrastim
- Other · Drug · Biological
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 30 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 1
- States / cities
- Monrovia, California
- Conditions
- Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma
- Interventions
- aldesleukin, filgrastim, cyclophosphamide, etoposide, radiation therapy, peripheral blood stem cell transplantation, bone marrow ablation with stem cell support
- Biological · Drug · Radiation + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 16 Years to 60 Years
- Enrollment
- 206 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1995
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- AIDS-Related Burkitt Lymphoma, AIDS-Related Diffuse Large B-cell Lymphoma, AIDS-Related Plasmablastic Lymphoma, AIDS-Related Primary Effusion Lymphoma, HIV Infection, AIDS Related Non-Hodgkin Lymphoma
- Interventions
- Prednisone, Rituximab, Etoposide, Doxorubicin Hydrochloride, Vincristine Sulfate, Cyclophosphamide, Filgrastim, Lentivirus Vector rHIV7-shI-TAR-CCR5RZ-transduced Hematopoietic Stem/Progenitor Cells
- Drug · Biological
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Mature B-Cell Lymphoma
- Interventions
- COPAD, COP, COPD M3, CYM, COP, COPADM8, CYVE
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2027
- U.S. locations
- 2
- States / cities
- San Diego, California • Memphis, Tennessee
- Conditions
- Leukemia, Lymphoma
- Interventions
- anti-thymocyte globulin, filgrastim, therapeutic allogeneic lymphocytes, cyclosporine, fludarabine phosphate, melphalan, methotrexate, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Metastatic Non-small Cell Lung Cancer
- Interventions
- Pembrolizumab Formulated with Berahyaluronidase Alfa, Pemetrexed, Cisplatin, Carboplatin, Paclitaxel, Nab-paclitaxel, Pembrolizumab, Filgrastim, Pegylated filgrastim
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 377 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • Clermont, Florida • Orange City, Florida + 6 more
- Conditions
- Multiple Myeloma
- Interventions
- Pegfilgrastim (Neulasta), Apheresis
- Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Breast Cancer
- Interventions
- cyclophosphamide, methotrexate, fluorouracil, PEG-filgrastim
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 70 Years · Female only
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 5
- States / cities
- Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
- Conditions
- Non-Hodgkin Lymphoma
- Interventions
- Carboplatin, Etoposide, Filgrastim, Ifosfamide, Leukapheresis, Plerixafor, Rituximab
- Drug · Biological · Procedure
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Lymphoma
- Interventions
- carmustine, cyclophosphamide, etoposide, peripheral blood stem cell transplantation, irradiation therapy, G-CSF, Cytarabine
- Drug · Procedure · Radiation + 1 more
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 75 Years
- Enrollment
- 473 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2019
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota